Published in

SAGE Publications, Antiviral Therapy, 6(15), p. 929-932, 2010

DOI: 10.3851/imp1633

Links

Tools

Export citation

Search in Google Scholar

Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen

Journal article published in 2010 by Angela Rago, Miriam Lichtner, Sergio Mecarocci, Raffaella Marocco, Natalia Cenfra, Valeria Belvisi, Cosmo Del Borgo, Cosmo Del Borgo, Giuseppe Cimino, Claudio Maria Mastroianni ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Entecavir and tenofovir disoproxil fumarate are potent and effective antiviral drugs that now represent recommended treatment options for chronic HBV infection. However, no or very limited clinical evidence is currently available on these drugs for the management of HBV reactivation in patients with haematological malignancies. Herein, we report a case of HBV reactivation in a patient with non-Hodgkin's lymphoma following a rituximab-based regimen, and who was successfully treated with a combination antiviral treatment including entecavir and tenofovir disoproxil fumarate.